THRUSDAY, MAY 7, 2020
STROKE PREVENTION
Session 1 – Atrial Fibrillation
Chairmen: S. Themistoclakis (Mestre), A. Raviele (Mestre)
15:00-15:15 Atrial fibrillation and OSAS
- China (Mestre)
15:15-15:30 Modern Strategies and Device to detect atrial fibrillation: I watch?
- Zecchin (Trieste)
15:30-15:45 Antiarrhythmic therapy in AF
- Verlato (Cittadella, PD)
15:45-16:00 The role of ETE for NOAC patients undergoing CVE: pros and cons
- Cucchini (Bassano del Grappa, VI)
16:00-16:15 Current indications for AF ablation
- Rossillo (Vicenza)
16:15-16:30 Discussion
Session 2 – NOAC in selected population
Chairmen: V. Pengo (Padova), Giuseppe Patti (Novara)
16:30-16:45 Elderly patient
- Bonanome (Venezia)
16:45-17:00 DES and NOAC
- Pasquetto (Padova)
17:00-17:15 Renal disease
- Bonmassari (Trento)
17:15-17:30 Pulmonary embolism and long term therapy
- Squizzato (Varese)
17:30-17:45 Discussion
17:45-18:15 Coffee Break
Session 3 – NAO: NEW STRATEGIES
Chairmen: A. Squizzato (Varese), F. Ribichini (Verona)
18:15-18:30 Compass Trial and Perypheral Arthery Disease
- Anselmi (Verona)
18:30-18:45 Entrust-AF PCI
- Patti (Novara)
18:45-19:00 Augustus trial, new therapeutic strategies in Coronary Artery Disease
- Ferri (Padova)
19:00-19:15 Anticoagulation in fragile patients: therapeutic options
- Pengo (Padova)
19:15-19:30 Discussion
19:30-20:00 Lectura magistralis
What is the future role of the aspirin for the cronic arteriopathy?
- Ribichini (Verona)
FRIDAY, MAY 8, 2020
AORTIC VALVE
Session 4 – Aortic Valve Interventions (part 1)
Chairmen: F. Bedogni (Milano), G. Gerosa (Padova)
9:00-9:15 NEW Insights From the PARTNER 3 Trial
- Caprioglio (Vicenza)
9:15-9:30 NEW Insights From the Evolut Low-Risk Trial
- Ribichini (Verona)
9:30-9:45 TAVR in lower risk patients: Interventional view
- Reimers (Milano)
9:45-10:00 TAVR in lower risk patients: Surgical view
- Mangino (Mestre)
10:00-10:15 Discussion
10:15-10:30 Coffee Break
Session 5 – Aortic Valve Interventions (part 2)
Chairmen: A. Ramondo (Brescia), F. Ribichini (Verona)
10:30-10:45 TAVR in moderate aortic stenosis with heart failure
- Fraccaro (Padova)
10:45-11:00 Strokes after TAVR are rare and cerebral protection is unnecessary
- Fiocca (Milano)
11:00-11:15 TAVR with high risk for coronary obstruction: management strategies
- Ramondo (Brescia)
11:15-11:30 TAVR for bicuspid aortic valve disease: clinical trial updates, anatomic considerations and optimizing procedural outcomes
- Cernetti (Treviso)
11:30-11:45 Discussion
MITRAL & TRICUSPID VALVES
Session 6 – Mitral valve regurgitation (part 1)
Chairmen: G. Tarantini (Padova), F. De Marco (Milano)
11:45-12:00 A post-COAPT update: new data and next steps for mitral valve repair
- Favero (Treviso)
12:00-12:15 MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results.
- Saccà (Mirano, VE)
12:15-12:30 Patient selection the echocardiography view
- Agricola (Milano, VE)
12:30-12:45 New device: “Pascal”-Edwards life science
- Berti (Massa)
12:45-13:00 Discussion
13:00-13:30 Lectura magistralis
What future for the aortic stenosis correction?
- Tarantini (Padova)
13:30-15:00 Lunch and poster session
MITRAL & TRICUSPID VALVES
Session 7 – Mitral regurgitation (part 2)
Chairmen: F. Caprioglio (Vicenza), L. Favero (Treviso)
15:00-15:15 Percutaneus anuloplasty: technique and results
- De Marco (Milano)
15:15-15:30 New borders: tricuspid valve
- Pasquetto (Padova)
15:30-15:45 Neocorde an efficacy tecnology
- Gerosa (Padova)
15:45-16:00 Latest techniques and results in minimally invasive mitral surgery
- Salvador (Vicenza)
16:00-16:15 Discussion
INTERATRIAL SEPTUM & LEFT ATRIAL APPENDAGE
Session 8 – Interatrial septum
Chairmen: F. Paladin (Venezia), G. Pesarini (Verona)
16:15-16:30 When should I close the PFO?
- Pedon (Cittadella, PD)
16:30-16:45 PFO occlusion: a large number of devices
- Rigatelli (Rovigo)
16:45-17:00 PFO and migraine
- Quatrale (Mestre)
17:00-17:15 DIA: when interventional cardiology and when surgery?
- Ronco (Mestre)
17:15-17:30 Discussion
17:30-17:45 Coffee Break
Session 9 – LAA
Chairmen: G. Minniti (Treviso), G. Pasquetto (Padova)
17:45-18:00 LAA occlusion criteria for intervention and expert consensus documents
- Pesarini (Verona)
18:00-18:15 LAA occlusion: device selection
- Di Pede (San Donà di Piave, VE)
18:15-18:30 Pre and post-procedure therapeutic option
- Turiano (Belluno)
18:45-19:00 Surgical option of the LAA occlusion
- Minniti (Treviso)
19:00-19:15 Discussion
19:15-19:45 Lectura magistralis | Galileo and Copernico, between Faith and Science
- Thiene (Padova)
SATURDAY MAY 9
CORONARY ARTERY DISEASE & PERIPHERICAL ARTERY DISEASE
Session 10 – CAD and new anti-platelet strategies
Chairmen: C. Bilato (Arzignano, VI), R. Valle (Chioggia, VE)
9:00-9:15 Long DAPT therapy: who and why?
- Bilato (Arzignano, VI)
9:15-9:30 Roule of aspirin: is it still necessary?
- Valle (Chioggia, VE)
9:30-9:45 NSTEMI: pre-treating or not?
- Cacciavillani (Padova)
9:45-10:00 Roule of cangrelor in ACS and stable CAD
- Muraglia (Trento)
10:00-10:15 Discussion
10:15- 10:45 Lectura magistralis | From aspirin to new antiplatelet agents
- Patrono (Roma)
10:45-11:00 Discussion
11.00-11:15 Coffee Break
Session 11 – Peripherical Artery Disease
Chairmen: C. Patrono (Roma), F. Grego (Padova)
11:15-11:30 New option on carotid artery disease
- Cagliari (Mestre)
11:30-11:45 New drug eluting stent for femoral artery: are a new frontier?
- Dorrucci (Mestre)
11:45-12:00 Distal PAD treatment strategy
- Antonello (Padova)
12:00-12:15 Diabetic foot: which is the best team?
- Manzi (Abano Terme, PD)
12:15-12:30 Discussion and closing remarks